Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria in the intestine refer to a diverse group of bacterial species capable of causing disease in the gastrointestinal tract. These organisms, distinct from commensal gut microbiota, can adhere to, colonize, and damage intestinal mucosa, frequently through the production of toxins or by triggering inflammatory responses. Common intestinal pathogens include species such as Escherichia coli (pathogenic strains), Salmonella enterica, Shigella spp., Campylobacter jejuni, Vibrio cholerae, and Clostridioides difficile. Their presence or overgrowth can result in infections ranging from mild gastritis to severe gastroenteritis and systemic illness. Treatment typically targets the bacteria directly with antibiotics or, more recently, interventions such as bacteriophage therapy and restoration of normal flora with probiotics or fecal microbiota transplantation. The broad categorization of "Pathogenic bacteria in intestine" does not represent a single molecular target but rather a collection of clinically important organisms with varied mechanisms of pathogenicity and interaction with both the host and commensal microbiota[2][3][4][5].
Direct killing by antibiotics (cell wall synthesis inhibition, protein synthesis inhibition, DNA replication inhibition); Competitive exclusion by commensal microbiota or probiotics; Lytic destruction by bacteriophages
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in intestine.